Rindopepimut is currently not available.
Our suppliers are constantly updating their product inventory and availability status. If you would like us to notify you when Rindopepimut becomes available, please fill out the form below.
*We value your privacy! We will never give, lease, sell or otherwise disclose your personal information. Period!
Information about SaveRxCanada.to
List of countries where we can ship Rindopepimut:
Latest news releases on Rindopepimut:
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate.
Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases.
Learn about the targeted therapeutics being developed by Celldex Therapeutics.
Press Releases. Year: Search: All Releases. Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors Nov 30, 2017 15.4 KB ...
Treatment with rindopepimut (Rintega) plus temozolomide failed to improve overall survival compared with temozolomide and a control for patients with newly diagnosed ...
Moved Permanently. The document has moved here.
Celldex's Rindopepimut (Rintega(R)) Receives FDA Breakthrough Therapy Designation for the Treatment of Adult Patients with EGFRvIII-positive Glioblastoma
Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The ...
This 2-arm, randomized, phase III study will investigate the efficacy and safety of the addition of rindopepimut (an experimental cancer vaccine that may act to ...
Rindopepimut ®: A promising immunotherapeutic for the treatment of glioblastoma multiforme. AM Swartz, QJ Li, and JH Sampson, MD, PhD ... Rindopepimut ® is emerging ...